This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignees: Nippi Corporation, The University of Tokyo. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2018
Title: Innovations of Katsumasa Iijima: A Pioneer in Recombinant Collagenases
Introduction: Katsumasa Iijima is a notable inventor based in Tokyo, Japan, recognized for his significant contributions to biotechnology through his invention of recombinant collagenases. His work has implications for cell and tissue dissociation, enhancing research and medical applications.
Latest Patents: Katsumasa Iijima holds a patent for recombinant collagenases with a stable specific activity and enzyme agents for cell and tissue dissociation. This innovative recombinant collagenase is characterized by a collagenase catalytic domain from the N terminus to the C terminus, a linker region sequence, and a distinct prepeptidase C terminal domain that enhances its performance. The recombinant collagenase exhibits high and stable specific activity, making it a valuable tool in various scientific applications.
Career Highlights: Iijima has had an illustrious career, with notable positions at Nippi Corporation and The University of Tokyo. His tenure at these esteemed institutions has allowed him to delve deeply into the research and development of biotechnological innovations, particularly in the field of collagenase applications.
Collaborations: Throughout his career, Katsumasa Iijima has collaborated with prominent colleagues, including Naoko Teramura and Osamu Hayashida. These partnerships have fostered significant advancements in the understanding and application of recombinant collagenases.
Conclusion: Katsumasa Iijima's contributions to the field of biotechnology through his patent on recombinant collagenases underline the importance of his work. His innovations promise to continue affecting scientific research and medical practices positively, securing his legacy as an influential inventor in Tokyo, Japan.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile